Otonomy, Inc.: Series B $38.5M

Posted in I - Series B, Q - 3Q10, R - WEST, X - Hearing Loss, X - Ménière's, X - Tinnitus, XX - CA

Otonomy (San Diego, CA) a clinical-stage biopharmaceutical company focused on, hearing and balance disorders such as Ménière’s disease, hearing loss, and tinnitus. closed a $38.5M Series B financing. Participants include Novo Ventures, RiverVest Venture Partners, Domain Associates and TPG Biotech.

Jun

2010

FoldRx Pharmaceutials, Inc.: Series C $29M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Cardiology, X - Neuro Degenerative, X - Protein Folding, XX - MA

FoldRx Pharmaceuticals (Cambridge) a clinical-stage small molecule company focused on protein misfolding and aggregation in transthyretin amyloid polyneuropathy and other neurodegenerative and cardiovascular diseases, closed a $29M Series C financing. Participants include Novo Ventures, Morgenthaler Ventures, HealthCare Ventures, Fidelity Biosciences, TPG Biotech, Alta Partners and Novartis Venture Funds.

Jun

2010

Logical Therapeutics, Inc.: Series C $16.9M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - GI, X - Inflammation, X - NSAID, XX - MA

Logical Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on rheumatoid arthritis, osteoarthritis, ankalosing spondylitis and other inflammatory diseasea, closed a $16.9M Series C financing. Participants include SV Life Sciences, Burrill & Company, Novo Ventures and Novitas Capital.

May

2010

Funxional Therapeutics, Ltd.: Series B $12.2M

Posted in I - Series B, Q - 2Q10, R - INTERNATIONAL, X - Asthma, X - COPD, X - Respiratory

Funxional Therapeutics (United Kingdom) a clinical-stage small molecule company focused on asthma, COPD and other respiratory disorders, closed a $12.2M Series B financing. Participants include Ventech, Index Ventures and Novo Ventures.

May

2010

NeuroTherapeutics Pharma, Inc.: Series B $43M

Posted in I - Series B, Q - 2Q10, R - MID WEST, X - CNS, X - Epilepsy, X - Pain, XX - IL

NeuroTherapeutics Pharma (Chicago, IL) a clinical-stage biopharmaceutical company focused on the CNS disorders of epilepsy, acute and neuropathic pain, closed a $43M Series B financing. Participants include Fidelity Biosciences, MPM Capital, S.R. One, Pfizer, Novo Ventures and Thomas McNerney & Partners.

Mar

2010

F-star Biotech, GmbH: Series A $10.8M

Posted in I - Series A, Q - 1Q10, R - INTERNATIONAL, X - Antibody, X - Therapeutic Platform

F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.

Feb

2010

Neomend, Inc.: Series D $30M

Posted in I - Series D, Q - 1Q10, R - WEST, X - Wound Healing, XX - CA

Neomend (Irvine, CA) a commercial-stage developer of sealant and adhesion-prevemtion products focused on the application to visceral pleura for open thoracotomy, closed a $30M Series D financing. Participants include Clarus Ventures, Sanderling Ventures, Novo Ventures, Vivo Ventures and Prospect Venture Partners.

Feb

2010

PTC Therapeutics, Inc.: Series E $50M

Posted in I - Series E, Q - 4Q09, R - NORTH EAST, X - CF, X - Hemophilia, X - Muscular Dystrophy, XX - NJ

PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Feb

2010

Ophthotech Corp.: Series B $30M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Opthalmology, XX - NJ

Ophthotech (Princeton, NJ) a clinical-stage biopharmaceutical company focused on ophthalmic therapies for wet and dry age-related macular degeneration, closed a $30M Series B financing. Participants include Clarus Ventures, SV Life Sciences, Novo Ventures and HBM BioVentures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Tarsa Therapeutics, Inc.: Series A $24M

Posted in I - Series A, Q - 4Q09, R - NORTH EAST, X - Osteoporosis, XX - NJ

Tarsa Therapeutics (Boonton, NJ) a clinical stage small molecule company focused on osteoporosis closed a $24M Series A financing. Participants include MVM Life Science Partners, Quaker BioVentures and Novo Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

to top of page...